Mylan Generic Infringes Endo's Frova Patent, Judge Says

Law360, Los Angeles (January 28, 2014, 4:17 PM EST) -- A Delaware federal judge on Tuesday granted Endo Pharmaceuticals Inc. a victory in its patent infringement suit against Mylan Pharmaceuticals Inc., ruling Endo’s patent for migraine medication Frova was valid and would be infringed by Mylan’s planned generic version.

U.S. District Judge Renee Marie Bumb rejected Mylan’s argument that the patent was invalid for anticipation, obviousness and failed written description. As part of its defense, Mylan claimed Endo’s patent did not properly describe how its drug should be used to treat migraines prophylactically, or before symptoms...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.